Abstract
Patients with acute lymphocytic leukemia (ALL) often experience relapse of their disease following standard treatment. Blinatumomab (Blincyto®) is a newly approved option for inducing remission in individuals with relapsed or refractory Philadelphia chromosome-negative B-cell ALL. This article provides an overview of blinatumomab, its benefits demonstrated in clinical trials, adverse effects, administration details, and the role of the oncology nurse in caring for and educating patients who receive blinatumomab. This article summarizes the results of two phase II studies on blinatumomab and provides practice implications for nurses caring for patients receiving this therapy. Attentive symptom monitoring and management are crucial. Individuals who achieve remission from blinatumomab can then be considered for stem cell transplantation and a chance for cure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
